Skip to main content Skip to navigation
FITC Mouse Anti-Human Bcl-2 Set

FITC Mouse Anti-Human Bcl-2 Set

(RUO)
FITC Mouse Anti-Human Bcl-2 Set
Profile of permeabilized peripheral blood lymphocytes analyzed on a FACScan™ (BDIS, San Jose, CA). Cells were stained with anti-human Bcl-2-FITC (clone Bcl-2/100) or an IgG1-FITC isotype control.
Profile of permeabilized peripheral blood lymphocytes analyzed on a FACScan™ (BDIS, San Jose, CA). Cells were stained with anti-human Bcl-2-FITC (clone Bcl-2/100) or an IgG1-FITC isotype control.
Product Details
Down Arrow Up Arrow


BD Pharmingen™
Human (QC Testing)
Intracellular staining (flow cytometry) (Routinely Tested)
RUO
AB_396382


Description

Programmed cell death (apoptosis) is a normal physiologic process which occurs during embryonic development as well as in maintenance of tissue homeostasis. The apoptotic program is characterized by certain morphological features. These include changes in the plasma membrane such as loss of membrane asymmetry and attachment, a condensation of the cytoplasm and nucleus, and internucleosomal cleavage of DNA. In the final stages, the dying cells become fragmented into "apoptotic bodies" which are rapidly eliminated by phagocytic cells without eliciting significant inflammatory damage to surrounding cells. Members of the Bcl-2 family play a major role in regulating the response of cells to apoptotic signals. Bcl-2 is considered to be novel among proto-oncogenes because it blocks apoptosis in many cell types. Bcl-2 is thought to provide selective survival advantage for cells by blocking apoptosis and thus may contribute to tumorigenesis. Bcl-2 is a 26 kDa intracellular, integral membrane protein found primarily in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membrane.

Clone Bcl-2/100 reacts with human Bcl-2. It does not cross-react with mouse Bcl-2. A synthetic peptide corresponding to amino acids 41-54  (GAAPAPGIFSSQPG) of human Bcl-2 was used as immunogen. This peptide sequence is not conserved between human and mouse. Clone Bcl-2/100 was initially characterized by western blotting and immunohistochemistry of frozen and paraffin-embedded tissue sections. Clone MOPC-21 is a mouse IgG1 isotype control. The MOPC-21 antibody has unknown specificity. The Bcl-2/100 and MOPC-21 FITC conjugates are matched in F/P ratios. The optimum F/P ratio was experimentally determined by flow cytometric analysis.

Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with FITC under optimum conditions, and unreacted FITC was removed. Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.

Product Notices

  1. This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
  2. This antibody has been optimized and preassayed with its matched isotype control to be used at the recommended volume of 20 ul/test. Titration of the reagents or substituting with other (non-matched) isotype control is NOT recommended.
  3. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  5. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
556357 Rev. 7
Components
Down Arrow Up Arrow
Description Quantity/Size Part Number EntrezGene ID
FITC Mouse Anti-Human Bcl-2 100 Tests (1 ea) 51-65114X N/A
FITC Mouse IgG1, κ Isotype Control 100 Tests (1 ea) 51-13854X-5 N/A
556357 Rev. 7
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 1993; 53(19):4701-4714. (Biology). View Reference
  2. Pezzella F, Jones M, Ralfkiaer E, Ersbøll J, Gatter KC, Mason DY. Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma. Br J Cancer. 1992; 65(1):87-89. (Clone-specific: Immunohistochemistry). View Reference
  3. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 1990; 137(2):225-232. (Clone-specific: Immunohistochemistry, Western blot). View Reference
  4. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993; 329(10):690-694. (Clone-specific: Immunohistochemistry). View Reference
  5. Reed JC, Meister L, Tanaka S, et al. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 1991; 51(24):6529-6538. (Clone-specific). View Reference
  6. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell. 1991; 65(7):1097-1098. (Biology). View Reference
  7. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997; 275(5303):1129-1132. (Biology). View Reference
View All (7) View Less
556357 Rev. 7

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.